CA1155058A - Method of preparing a composition useful in cosmetic and medicine - Google Patents
Method of preparing a composition useful in cosmetic and medicineInfo
- Publication number
- CA1155058A CA1155058A CA000361137A CA361137A CA1155058A CA 1155058 A CA1155058 A CA 1155058A CA 000361137 A CA000361137 A CA 000361137A CA 361137 A CA361137 A CA 361137A CA 1155058 A CA1155058 A CA 1155058A
- Authority
- CA
- Canada
- Prior art keywords
- acid
- solution
- nitric acid
- nitrite
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 107
- 238000000034 method Methods 0.000 title claims abstract description 38
- 239000002537 cosmetic Substances 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 title claims abstract description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 83
- 239000000243 solution Substances 0.000 claims abstract description 74
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims abstract description 72
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims abstract description 66
- 229910017604 nitric acid Inorganic materials 0.000 claims abstract description 65
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 63
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims abstract description 60
- 239000002253 acid Substances 0.000 claims abstract description 33
- 239000004310 lactic acid Substances 0.000 claims abstract description 32
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 32
- 235000006408 oxalic acid Nutrition 0.000 claims abstract description 20
- 239000010949 copper Substances 0.000 claims abstract description 16
- 229910052751 metal Inorganic materials 0.000 claims abstract description 16
- 239000002184 metal Substances 0.000 claims abstract description 16
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229910052802 copper Inorganic materials 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 11
- WLZRMCYVCSSEQC-UHFFFAOYSA-N cadmium(2+) Chemical compound [Cd+2] WLZRMCYVCSSEQC-UHFFFAOYSA-N 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 150000007513 acids Chemical class 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 claims description 10
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 8
- 229910052793 cadmium Inorganic materials 0.000 claims description 8
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims description 8
- 150000007524 organic acids Chemical class 0.000 claims description 6
- 229910052709 silver Inorganic materials 0.000 claims description 6
- 239000004332 silver Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 150000001661 cadmium Chemical class 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- 229910001431 copper ion Inorganic materials 0.000 claims description 5
- 229940116333 ethyl lactate Drugs 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 230000001530 keratinolytic effect Effects 0.000 claims description 4
- 125000005907 alkyl ester group Chemical group 0.000 claims description 3
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000007790 solid phase Substances 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims 2
- 238000007865 diluting Methods 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001261 hydroxy acids Chemical class 0.000 claims 1
- 235000011054 acetic acid Nutrition 0.000 abstract description 22
- 238000011282 treatment Methods 0.000 abstract description 19
- 230000003902 lesion Effects 0.000 abstract description 16
- 230000001590 oxidative effect Effects 0.000 abstract description 13
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 abstract description 12
- 201000011510 cancer Diseases 0.000 abstract description 4
- 210000004400 mucous membrane Anatomy 0.000 abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 26
- 229960000583 acetic acid Drugs 0.000 description 25
- 210000003491 skin Anatomy 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 22
- 239000007789 gas Substances 0.000 description 21
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 18
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Substances [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 15
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 14
- 229910002651 NO3 Inorganic materials 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 239000000306 component Substances 0.000 description 13
- 239000013078 crystal Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000004033 plastic Substances 0.000 description 13
- 229920003023 plastic Polymers 0.000 description 13
- 229940107700 pyruvic acid Drugs 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 9
- 239000004202 carbamide Substances 0.000 description 9
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 9
- GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 8
- 235000010288 sodium nitrite Nutrition 0.000 description 8
- 208000000260 Warts Diseases 0.000 description 7
- 238000002845 discoloration Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 201000010153 skin papilloma Diseases 0.000 description 7
- -1 aliphatic hydroxy acids Chemical class 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004040 coloring Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 5
- XIEPJMXMMWZAAV-UHFFFAOYSA-N cadmium nitrate Inorganic materials [Cd+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XIEPJMXMMWZAAV-UHFFFAOYSA-N 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 5
- 239000011976 maleic acid Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010020649 Hyperkeratosis Diseases 0.000 description 4
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- QOYRNHQSZSCVOW-UHFFFAOYSA-N cadmium nitrate tetrahydrate Chemical compound O.O.O.O.[Cd+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O QOYRNHQSZSCVOW-UHFFFAOYSA-N 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 239000003518 caustics Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 229940093915 gynecological organic acid Drugs 0.000 description 4
- ROBFUDYVXSDBQM-UHFFFAOYSA-N hydroxymalonic acid Chemical compound OC(=O)C(O)C(O)=O ROBFUDYVXSDBQM-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 229960004889 salicylic acid Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical class [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 description 4
- ZFYIQPIHXRFFCZ-QMMMGPOBSA-N (2s)-2-(cyclohexylamino)butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC1CCCCC1 ZFYIQPIHXRFFCZ-QMMMGPOBSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- XIOUDVJTOYVRTB-UHFFFAOYSA-N 1-(1-adamantyl)-3-aminothiourea Chemical compound C1C(C2)CC3CC2CC1(NC(=S)NN)C3 XIOUDVJTOYVRTB-UHFFFAOYSA-N 0.000 description 2
- JRMAQQQTXDJDNC-UHFFFAOYSA-M 2-ethoxy-2-oxoacetate Chemical compound CCOC(=O)C([O-])=O JRMAQQQTXDJDNC-UHFFFAOYSA-M 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 235000010585 Ammi visnaga Nutrition 0.000 description 2
- 244000153158 Ammi visnaga Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910052787 antimony Inorganic materials 0.000 description 2
- 229940075103 antimony Drugs 0.000 description 2
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 206010016629 fibroma Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 206010024217 lentigo Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Inorganic materials [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 239000010875 treated wood Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 229960001939 zinc chloride Drugs 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 206010004950 Birth mark Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000003643 Callosities Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 241000699662 Cricetomys gambianus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 1
- MWHHJYUHCZWSLS-UHFFFAOYSA-N FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F Chemical compound FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F MWHHJYUHCZWSLS-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000013270 Palmar hyperkeratosis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000014417 Plantar hyperkeratosis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- AZFNGPAYDKGCRB-XCPIVNJJSA-M [(1s,2s)-2-amino-1,2-diphenylethyl]-(4-methylphenyl)sulfonylazanide;chlororuthenium(1+);1-methyl-4-propan-2-ylbenzene Chemical compound [Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC(C)=CC=C1S(=O)(=O)[N-][C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 AZFNGPAYDKGCRB-XCPIVNJJSA-M 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- IZFOVFBRJMXESP-UHFFFAOYSA-N acetic acid;nitrous acid Chemical compound ON=O.CC(O)=O IZFOVFBRJMXESP-UHFFFAOYSA-N 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- CGBYBGVMDAPUIH-UHFFFAOYSA-N acide dimethylmaleique Natural products OC(=O)C(C)=C(C)C(O)=O CGBYBGVMDAPUIH-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- LVXNTESFNBTPMI-UHFFFAOYSA-L cadmium(2+);dinitrite Chemical compound [Cd+2].[O-]N=O.[O-]N=O LVXNTESFNBTPMI-UHFFFAOYSA-L 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026735 cervix disease Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 229940018557 citraconic acid Drugs 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- CGBYBGVMDAPUIH-ARJAWSKDSA-N dimethylmaleic acid Chemical compound OC(=O)C(/C)=C(/C)C(O)=O CGBYBGVMDAPUIH-ARJAWSKDSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940117360 ethyl pyruvate Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- CWKLZLBVOJRSOM-UHFFFAOYSA-N methyl pyruvate Chemical compound COC(=O)C(C)=O CWKLZLBVOJRSOM-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- XEEVLJKYYUVTRC-UHFFFAOYSA-N oxomalonic acid Chemical compound OC(=O)C(=O)C(O)=O XEEVLJKYYUVTRC-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004304 potassium nitrite Substances 0.000 description 1
- 235000010289 potassium nitrite Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000002673 radiosurgery Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- ZEGFMFQPWDMMEP-UHFFFAOYSA-N strontium;sulfide Chemical compound [S-2].[Sr+2] ZEGFMFQPWDMMEP-UHFFFAOYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000010876 untreated wood Substances 0.000 description 1
- AYTGUZPQPXGYFS-UHFFFAOYSA-N urea nitrate Chemical compound NC(N)=O.O[N+]([O-])=O AYTGUZPQPXGYFS-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH8713/79 | 1979-09-27 | ||
| CH871379A CH629100A5 (de) | 1979-09-27 | 1979-09-27 | Hautpraeparat. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1155058A true CA1155058A (en) | 1983-10-11 |
Family
ID=4343859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000361137A Expired CA1155058A (en) | 1979-09-27 | 1980-09-26 | Method of preparing a composition useful in cosmetic and medicine |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US4595591A (en:Method) |
| EP (1) | EP0026532B1 (en:Method) |
| JP (1) | JPS5659706A (en:Method) |
| KR (1) | KR850001724B1 (en:Method) |
| AR (1) | AR224654A1 (en:Method) |
| AT (1) | ATE20183T1 (en:Method) |
| AU (1) | AU538878B2 (en:Method) |
| CA (1) | CA1155058A (en:Method) |
| CH (1) | CH629100A5 (en:Method) |
| DE (1) | DE3071629D1 (en:Method) |
| DK (1) | DK161012C (en:Method) |
| EG (1) | EG15021A (en:Method) |
| ES (1) | ES8107020A1 (en:Method) |
| FI (1) | FI73129C (en:Method) |
| GR (1) | GR70008B (en:Method) |
| IL (1) | IL61136A (en:Method) |
| IN (1) | IN154851B (en:Method) |
| PH (1) | PH18810A (en:Method) |
| PL (1) | PL133116B1 (en:Method) |
| SU (1) | SU1382394A3 (en:Method) |
| ZA (1) | ZA805990B (en:Method) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0151201B1 (de) * | 1982-10-08 | 1986-11-12 | Zvonko Pestelic | Keratolytisches Mittel, geeignet zum Entfernen von Warzen |
| CH673225A5 (en:Method) * | 1986-04-22 | 1990-02-28 | Sanosil Ag | |
| US4681687A (en) * | 1986-10-20 | 1987-07-21 | Nalco Chemical Company | Use of alkali metal nitrites to inhibit H2 S formation in flue gas desulfurization system sludges |
| US4758426A (en) * | 1987-06-11 | 1988-07-19 | Ramsdell Bruce V | Therapeutic toilet solution and method of dispersion |
| US5053024A (en) * | 1989-10-23 | 1991-10-01 | Israel Dvoretzky | Application system and method for treating warts |
| GB9308103D0 (en) * | 1993-04-20 | 1993-06-02 | Unilever Plc | Cosmetic composition |
| MY128187A (en) * | 1993-06-23 | 2007-01-31 | Icn Switzerland Ag | Preparation for skin and mucous membrane |
| US5456904A (en) * | 1993-06-28 | 1995-10-10 | The Procter & Gamble Company | Photoprotection compositions comprising certain chelating agents |
| US5407958A (en) * | 1993-07-30 | 1995-04-18 | Beauticontrol Cosmetics, Inc. | Therapeutic skin composition |
| US6418556B1 (en) | 1993-09-09 | 2002-07-09 | United Video Properties, Inc. | Electronic television program guide schedule system and method |
| FR2715845B1 (fr) * | 1994-02-04 | 1996-03-29 | Oreal | Composition cosmétique et/ou dermatologique contenant du vinaigre. |
| US6709681B2 (en) | 1995-02-17 | 2004-03-23 | Aberdeen University | Acidified nitrite as an antimicrobial agent |
| EP0717984B1 (en) * | 1994-12-20 | 2004-11-03 | Unilever Plc | Lactate dehydrogenase inhibitors in cosmetic compositions |
| SE9700617D0 (sv) * | 1997-02-21 | 1997-02-21 | Kjell Alving | New composition |
| GB9905425D0 (en) * | 1999-03-09 | 1999-05-05 | Queen Mary & Westfield College | Pharmaceutical composition |
| RU2173988C1 (ru) * | 2000-10-09 | 2001-09-27 | Рушан Фатихович Айзятулов | Лекарственная композиция для локального лечения доброкачественных опухолей и предраковых заболеваний кожи |
| US6585742B2 (en) | 2001-05-08 | 2003-07-01 | Dowling B. Stough | Wart removal method and device |
| US20060200174A1 (en) * | 2001-05-08 | 2006-09-07 | Stough Dowling B | Wart removal method and device |
| EP1455888B1 (en) | 2001-08-29 | 2009-04-29 | PharmaKodex Limited | Topical administration device |
| US7128903B2 (en) | 2001-10-03 | 2006-10-31 | Innovative Pharmaceutical Concepts (Ipc) Inc. | Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucous membranes and methods and kits using same |
| US20030175362A1 (en) * | 2002-01-07 | 2003-09-18 | Kross Robert D. | Disinfecting nitrous acid compositions and process for using the same |
| WO2003080110A1 (es) * | 2002-03-22 | 2003-10-02 | Suarez Mendoza Ramon | Liquido topico destructor de tejido patogeno |
| US7780992B2 (en) * | 2002-12-08 | 2010-08-24 | Tareq Abduljalil Albahri | Antiviral medicament |
| UA82254C2 (uk) * | 2003-12-03 | 2008-03-25 | Валодя Падиурашвили | Склад та спосіб одержання композиції, фармацевтична композиція та її застосування |
| US7258875B2 (en) * | 2003-12-04 | 2007-08-21 | Chiou Consulting, Inc. | Compositions and methods for topical treatment of skin infection |
| US7311928B2 (en) * | 2003-12-09 | 2007-12-25 | Briant Burke | Topical compositions containing tea tree oil for treatment of viral lesions |
| AU2006204585B2 (en) * | 2005-01-06 | 2011-04-14 | Bennett, David Mr | Composition and method for treatment of residues in pumping, bore, and reticulation equipment |
| WO2006072134A1 (en) * | 2005-01-06 | 2006-07-13 | David Bennett | Composition and method for treatment of residues in pumping, bore, and reticulation equipment |
| EP2082744B1 (fr) | 2008-01-25 | 2011-09-21 | Auriga International | Composition pharmaceutique comprenant de l'acide nitrique et un sel de zinc et son dispositif médical pour le traitement de lésions cutanées |
| RU2440816C1 (ru) * | 2010-12-09 | 2012-01-27 | Общество С Ограниченной Ответственностью "Оксигон" | Лекарственное средство, способ его получения и способ применения |
| US9446068B2 (en) | 2011-04-22 | 2016-09-20 | Obschestvos S Ogranitchennoi Otvetstvennostju “Oxygon” | Method of production of the stable selenium-comprising pharmaceutical composition with a high selenium level |
| RU2482856C2 (ru) | 2011-08-05 | 2013-05-27 | Общество С Ограниченной Ответственностью "Оксигон" | Комплексное соединение 2-хлорпропионата цинка и 2-хлорпропионовой кислоты, фармацевтическая композиция для лечения заболеваний кожи, способ ее получения и способ лечения поражений кожи, ногтей и видимых слизистых |
| US20230052709A1 (en) * | 2021-07-29 | 2023-02-16 | Alexander Sepper | Topical antiviral liquid for treatment of warts |
| US12161661B2 (en) * | 2022-07-25 | 2024-12-10 | Alexander Sepper | Topical composition for destroying, in vivo, an external hyperplastic tissue, such as, but not limited to, a viral skin lesion, such as, but not limited to, a viral wart |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3879537A (en) * | 1973-09-04 | 1975-04-22 | Scott Eugene J Van | Treatment of ichthyosiform dermatoses |
| US3988470A (en) * | 1974-02-25 | 1976-10-26 | Scott Eugene J Van | Treatment of palmar and plant disturbed keratosis |
-
1979
- 1979-09-27 CH CH871379A patent/CH629100A5/de not_active IP Right Cessation
-
1980
- 1980-09-22 AT AT80200887T patent/ATE20183T1/de not_active IP Right Cessation
- 1980-09-22 EG EG580/80A patent/EG15021A/xx active
- 1980-09-22 EP EP80200887A patent/EP0026532B1/de not_active Expired
- 1980-09-22 DE DE8080200887T patent/DE3071629D1/de not_active Expired
- 1980-09-24 IL IL61136A patent/IL61136A/xx not_active IP Right Cessation
- 1980-09-25 ES ES495330A patent/ES8107020A1/es not_active Expired
- 1980-09-26 PL PL1980226939A patent/PL133116B1/pl unknown
- 1980-09-26 AR AR282676A patent/AR224654A1/es active
- 1980-09-26 DK DK407480A patent/DK161012C/da not_active IP Right Cessation
- 1980-09-26 FI FI803037A patent/FI73129C/fi not_active IP Right Cessation
- 1980-09-26 GR GR62969A patent/GR70008B/el unknown
- 1980-09-26 PH PH24641A patent/PH18810A/en unknown
- 1980-09-26 CA CA000361137A patent/CA1155058A/en not_active Expired
- 1980-09-26 AU AU62758/80A patent/AU538878B2/en not_active Ceased
- 1980-09-26 KR KR1019800003749A patent/KR850001724B1/ko not_active Expired
- 1980-09-26 SU SU802990878A patent/SU1382394A3/ru active
- 1980-09-26 ZA ZA00805990A patent/ZA805990B/xx unknown
- 1980-09-26 IN IN698/DEL/80A patent/IN154851B/en unknown
- 1980-09-27 JP JP13509480A patent/JPS5659706A/ja active Granted
-
1983
- 1983-02-07 US US06/464,371 patent/US4595591A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| KR850001724B1 (ko) | 1985-12-07 |
| KR830003210A (ko) | 1983-06-18 |
| EP0026532B1 (de) | 1986-06-04 |
| DK407480A (da) | 1981-03-28 |
| ES495330A0 (es) | 1981-10-01 |
| ZA805990B (en) | 1981-09-30 |
| DK161012C (da) | 1991-10-28 |
| FI803037A7 (fi) | 1981-03-28 |
| EG15021A (en) | 1985-06-30 |
| AU538878B2 (en) | 1984-08-30 |
| ATE20183T1 (de) | 1986-06-15 |
| AR224654A1 (es) | 1981-12-30 |
| SU1382394A3 (ru) | 1988-03-15 |
| DE3071629D1 (en) | 1986-07-10 |
| IL61136A0 (en) | 1980-11-30 |
| GR70008B (en:Method) | 1982-07-23 |
| EP0026532A2 (de) | 1981-04-08 |
| AU6275880A (en) | 1981-04-09 |
| DK161012B (da) | 1991-05-21 |
| IL61136A (en) | 1984-02-29 |
| JPH0129773B2 (en:Method) | 1989-06-14 |
| IN154851B (en:Method) | 1984-12-15 |
| CH629100A5 (de) | 1982-04-15 |
| EP0026532A3 (en) | 1981-08-19 |
| PL226939A1 (en:Method) | 1981-08-21 |
| PL133116B1 (en) | 1985-05-31 |
| FI73129B (fi) | 1987-05-29 |
| US4595591A (en) | 1986-06-17 |
| ES8107020A1 (es) | 1981-10-01 |
| PH18810A (en) | 1985-09-27 |
| JPS5659706A (en) | 1981-05-23 |
| FI73129C (fi) | 1987-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1155058A (en) | Method of preparing a composition useful in cosmetic and medicine | |
| Klasen | Historical review of the use of silver in the treatment of burns. I. Early uses | |
| KR100297965B1 (ko) | 피부및점막용제제 | |
| US3821370A (en) | Topical composition for treating seborrheic keratosis | |
| HU213450B (en) | Gel contains gelatin and process for producing it | |
| CZ178196A3 (en) | Pharmaceutical preparation for papulopustular punctual therapy | |
| JP2004518715A (ja) | 先端線維性軟ゆうの緩和 | |
| CA2683769C (en) | Composition for removing a tattoo | |
| JPH01254609A (ja) | 安定化したアスコルビン酸を含有する化粧料組成物 | |
| US12156927B2 (en) | Formulation for odontological and dermatological use containing trchloroacetate salts and hydroxyacids | |
| CN117717492B (zh) | 一种修复腋窝微生态的生物制剂及其制备方法和应用 | |
| Weiner et al. | Preclinical and clinical evaluation of topical acid products for skin tumors | |
| RU2183113C1 (ru) | Средство-гидросульфат графита и способ лечения больных с доброкачественными и злокачественными опухолями кожи (варианты) | |
| RU2826643C2 (ru) | Композиции для одонтологического и дерматологического применения, содержащие трихлорацетатные соли и гидроксикислоты | |
| Harmon et al. | Trichloroacetic acid | |
| Bachot et al. | Superficial and medium-depth chemical peels | |
| Graham et al. | Dichloroacetic Acid in Dermatology | |
| Jaya | A Prospective, Split Mouth, Double Blinded Trial to Compare and Evaluate the Effectiveness of Cryosurgery, Diode Laser Therapy and Conventional Surgical Procedure in the Management of Gingival Hyperpigmentation:-A Clinical and Histological Study | |
| CN118236396A (zh) | 一种no供体型组合物及其制备方法与应用 | |
| CN1371675A (zh) | 一种护肤去斑霜制剂及其制备方法 | |
| GB2170405A (en) | Hair growth promotion | |
| CONSTANTINE | A COMBINED TISSUE STAIN FOR THE SELECTIVE STAINING OF COLLAGEN, ELASTIC FIBERS AND ACIDIC |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |